Walleye Capital’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Walleye Capital’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,727	Closed	-$217K	–	5601
2023 Q2	$217K	Buy	+4,727	New	+$958K	﹤0.01%	3026

Other funds holding PBLA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Walleye Capital's PBLA Position: Q3 2023 in Review

Walleye Capital sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q3 2023, closing a stake of 4,727 shares — an estimated $217K sold.

Walleye Capital first reported a position in PBLA in Q2 2023 and held it in 1 quarter. The position peaked at $217K in Q2 2023. 5 funds tracked by Wall St. Rank hold PBLA as of Q3 2023.

Walleye Capital reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Walleye Capital sold 4,727 Panbela Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $217K.
Walleye Capital first reported a position in Panbela Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
Walleye Capital's Panbela Therapeutics, Inc. Common Stock position peaked at $217K in Q2 2023.
5 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Walleye Capital's 13F filing for Q3 2023, filed 14 Nov 2023.